SCHEMBL3530076

SCHEMBL3530076

Cc1nc(-c2ccc(C(F)(F)F)nc2)sc1C(OCc1ccc(C#N)c(Cl)c1)C(F)(F)F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 4/20 0.34
XDH P47989 2/20 0.33
ABCC4 O15439 1/20 0.33
ABCB11 O95342 1/20 0.33
PGR P06401 1/20 0.33
CHRM1 P11229 1/20 0.33
PDE4A P27815 1/20 0.33
BLVRB P30043 1/20 0.33
TARBP2 Q15633 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
ABCG2 Q9UNQ0 1/20 0.33
PPARD Q03181 2/20 0.32
PTGES O14684 1/20 0.32
CNR1 P21554 1/20 0.32
RET P07949 1/20 0.32
MGLL Q99685 1/20 0.32
CYP11B1 P15538 3/20 0.32
PIK3CD O00329 1/20 0.32
PIK3CA P42336 1/20 0.32
PIK3CB P42338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3530663 0.93 PPARD (0.33) CYP11B2XDHABCC4ABCB11PGR
SCHEMBL3533795 0.91 RET (0.35) CYP11B2XDHABCC4ABCB11PGR
SCHEMBL3532535 0.90 XDH (0.33) XDHABCC4ABCB11PGRCHRM1
SCHEMBL3526025 0.88 RET (0.35) XDHABCC4ABCB11PGRCHRM1
SCHEMBL3530458 0.86 PGGT1B (0.33) XDHABCC4ABCB11PGRCHRM1
SCHEMBL3527868 0.86 HRH3 (0.38) PPARDPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL3530081 0.81 FNTA (0.37) CYP11B2XDHABCC4ABCB11PGR
SCHEMBL3530903 0.80 AR (0.35) XDHABCC4ABCB11PGRCHRM1
SCHEMBL11958548 0.80 PPARD (0.41) PPARD
SCHEMBL3530754 0.79 PTGES (0.38) PTGESCNR1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931337-B1 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2013-10-23 EP disclosed
US-7709481-B2 Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals SANOFI-AVENTIS (FR) 2010-05-04 US disclosed
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
EP-1931337-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2008-06-18 EP disclosed
WO-2007039177-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals PPARD, PPARA, PPARG CYP11B2 45/4885XDH 1949/4885ABCC4 362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.